

- Patients should continue therapy and follow the recommendations of their physicians.
- If bleeding is not controlled with usual doses, patients should consult their physician immediately.

A workshop is planned in the first quarter of 2006 to review current knowledge on FVIII products and inhibitor development. The EMEA will bring together a panel of recognised experts in this field, interested parties, patient associations and regulators.

The aim of the workshop will be to discuss standardization of requirements, definitions and methods used in pre-and post-marketing studies with PTPs and previously untreated patients for FVIII products, since these studies are an important tool for investigating the safety of such products.

The conclusions of this workshop will be made available on the EMEA website.

For information, please contact

Dr Panos Tsintis
Head of Sector Pharmacovigilance and Post-Authorisation
Safety and Efficacy of Medicines

